Tau is a pathogenic protein burden associated with neurodegeneration, especially alzheimers disease, where it is described as a major component of disease pathology alongside amyloid-beta. Its primary relevance here is as a disease-linked protein target whose burden can be measured indirectly by imaging, with quantitative susceptibility mapping (quantitative susceptibility mapping) showing a quadrant-specific association in the substantia nigra. In a study of the substantia nigra, tau burden correlated with QSM in the ventromedial quadrant and showed both direct and indirect effects mediated through iron, highlighting a mechanistic link between protein pathology and metal-related susceptibility changes. Recent literature also frames tau as a target for engineered nanobody formats, supporting drug-delivery and functional-screening strategies in Alzheimer’s disease. More broadly, tau post-translational modifications are being explored as therapeutic and mechanistic nodes in Alzheimer’s disease, reflecting ongoing efforts to connect protein pathology with intervention design.
Neurodegeneration / Alzheimer’s disease
- Tau deposition is described as part of alzheimers disease pathology alongside amyloid-beta, emphasizing its role as a major pathogenic protein burden. (PMID:41944134)
- A 2026 CNS & neurological disorders drug targets review (PMID:41944134) highlighted pathogenic protein post-translational modifications as mechanisms and therapeutic strategy points relevant to tau.
- Engineered nanobody formats were discussed as a way to specifically target tau for drug delivery systems in Alzheimer’s disease. (PMID:41568664)
- Functional screening and nanobody engineering were presented as approaches to improve tau targeting in Alzheimer’s disease. (PMID:41568664)
Imaging / Iron-related pathology
- Tau showed a quadrant-specific association with quantitative susceptibility mapping in the substantia nigra, with the strongest relationship in the ventromedial quadrant. (PMID:41708563)
- The same Acta Neuropathologica study (PMID:41708563) reported that tau had both direct and indirect effects on QSM via iron.
- Neuropathologic protein burden, including tau, was linked to susceptibility changes in the substantia nigra, supporting QSM as a marker of underlying pathology. (PMID:41708563)